CDK Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of CDK Global to Brookfield Business Partners

MONSEY, N.Y., April 07, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of CDK Global, Inc. (ticker: CDK) (CDK) acted in the best interests of CDK shareholders in approving the sale of CDK to Brookfield Business Partners (Brookfield) for $54.87 per share in cash in a tender offer.

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Thursday, April 7, 2022
Information
Tags: 
GLOBE, CDK Global, Wall Street, Brookfield Business Partners, Fraud, Wohl, Sale, Acquisition, CDK, Security (finance), Private investigator
Geotags: 
MONSEY, NY, US, NEW YORK CITY
Stock Symbol: 
NASDAQ:CDK
Summary
Key Points: 
  • MONSEY, N.Y., April 07, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of CDK Global, Inc. (ticker: CDK) (CDK) acted in the best interests of CDK shareholders in approving the sale of CDK to Brookfield Business Partners (Brookfield) for $54.87 per share in cash in a tender offer.
  • On April 7, 2022, CDK announced an agreement for Brookfield to purchase all of the outstanding shares of CDK for $54.87 per share in cash in a tender offer.
  • Our investigation concerns whether CDKs board acted in the best interests of CDK shareholders in approving the sale to Brookfield, including whether the acquisition price adequately compensates CDK shareholders, and whether all material information regarding the transaction has been fully disclosed.
  • Please visit our website, www.wohlfruchter.com , to learn more about our Firm, or contact one of our partners.



MONSEY, N.Y., April 07, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of CDK Global, Inc. (ticker: CDK) (“CDK”) acted in the best interests of CDK shareholders in approving the sale of CDK to Brookfield Business Partners (“Brookfield”) for $54.87 per share in cash in a tender offer.

If you remain a CDK shareholder and have questions about your legal rights, you may contact our firm at the following link to discuss your options at no charge:

https://wohlfruchter.com/cases/cdk-global/

Alternatively, you may contact us by phone at 866-833-6245, or via email at [email protected].

Why is there an investigation?
On April 7, 2022, CDK announced an agreement for Brookfield to purchase all of the outstanding shares of CDK for $54.87 per share in cash in a tender offer. The agreement has been approved by the CDK board.

Our investigation concerns whether CDK’s board acted in the best interests of CDK shareholders in approving the sale to Brookfield, including whether the acquisition price adequately compensates CDK shareholders, and whether all material information regarding the transaction has been fully disclosed.

In particular, according to an analysis of Wall Street CDK price targets in the last 90 days published on Seeking Alpha, CDK has an average target price of $56.83 per share, and a high target price of $65.00 per share, both of which are above the price that Brookfield has agreed to pay.

About Wohl & Fruchter
Wohl & Fruchter LLP, with offices in New York City and Monsey, has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

Contact:
Wohl & Fruchter LLP
Joshua E. Fruchter
Toll Free 866.833.6245
[email protected]
www.wohlfruchter.com
Copyright: 
2022 GlobeNewswire, Inc.. All Rights Reserved.